Published in Infect Immun on August 01, 2005
Quantitative and qualitative preparations of bacterial outer membrane vesicles. Methods Mol Biol (2013) 1.04
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
"Western blotting": electrophoretic transfer of proteins from sodium dodecyl sulfate--polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Anal Biochem (1981) 71.15
Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med (1969) 13.87
Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med (1969) 9.01
Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet (1991) 6.26
Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in man. J Clin Invest (1979) 3.61
Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr (2000) 3.53
Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann (1991) 3.32
Modulation of cell surface sialic acid expression in Neisseria meningitidis via a transposable genetic element. EMBO J (1996) 2.80
Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine. J Clin Microbiol (1986) 2.67
Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet (1992) 2.52
Isolation and characterization of a native cell wall complex from Neisseria meningitidis. Infect Immun (1972) 2.43
Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine (1995) 2.06
A general approach to standardization of the solid-phase radioimmunoassay for quantitation of class-specific antibodies. J Immunol Methods (1981) 1.93
Expression of the L8 lipopolysaccharide determinant increases the sensitivity of Neisseria meningitidis to serum bactericidal activity. Infect Immun (1994) 1.55
Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine. Vaccine (1996) 1.54
Effect of the (alpha 2-->8)-linked polysialic acid capsule on adherence of Neisseria meningitidis to human mucosal cells. J Infect Dis (1993) 1.51
Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans. Infect Immun (1998) 1.42
Identification of a genetic locus involved in the biosynthesis of N-acetyl-D-mannosamine, a precursor of the (alpha 2-->8)-linked polysialic acid capsule of serogroup B Neisseria meningitidis. J Bacteriol (1994) 1.33
Immunogenicity of intranasally administered meningococcal native outer membrane vesicles in mice. Infect Immun (1999) 1.17
Protective studies with group A streptococcal M protein vaccine. III. Challenge of volunteers after systemic or intranasal immunization with Type 3 or Type 12 group A Streptococcus. J Infect Dis (1978) 1.16
Safety and immunogenicity testing of an intranasal group B meningococcal native outer membrane vesicle vaccine in healthy volunteers. Vaccine (1999) 1.07
Rubella immunization of volunteers via the respiratory tract. Infect Immun (1973) 1.02
Outer membrane vesicles from group B meningococci are strongly immunogenic when given intranasally to mice. Vaccine (1999) 1.01
Confirmation of suspicious cases of meningococcal meningitis by PCR and enzyme-linked immunosorbent assay. J Clin Microbiol (1997) 0.97
Immunogenicity and safety testing of a group B intranasal meningococcal native outer membrane vesicle vaccine. Infect Immun (2002) 0.93
Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal. Drugs R D (2003) 0.86
Effect of meningococcal endotoxin in a rabbit model of shock. Circ Shock (1992) 0.80
Antigenicity of a polysaccharide vaccine from Neisseria meningitidis administered intranasally. J Infect Dis (1973) 0.77
Description and nomenclature of Neisseria meningitidis capsule locus. Emerg Infect Dis (2013) 1.47
Genetic and antigenic analysis of invasive serogroup Y Neisseria meningitidis isolates collected from 1999 to 2003 in Canada. J Clin Microbiol (2007) 1.30
Distribution of serogroups of Neisseria meningitidis and antigenic characterization of serogroup Y meningococci in Canada, January 1, 1999 to June 30, 2001. Can J Infect Dis (2002) 1.14
Invasive meningococcal disease in Quebec, Canada, due to an emerging clone of ST-269 serogroup B meningococci with serotype antigen 17 and serosubtype antigen P1.19 (B:17:P1.19). J Clin Microbiol (2006) 1.11
Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine. Vaccine (2010) 1.08
Serological specificities of murine hybridoma monoclonal antibodies against Neisseria meningitidis serogroups B, C, Y, and W135 and evaluation of their usefulness as serogrouping reagents by indirect whole-cell enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol (2005) 1.05
Immunogenicity and safety testing of a group B intranasal meningococcal native outer membrane vesicle vaccine. Infect Immun (2002) 0.93
Meningococcal serogroup B vaccines: will they live up to expectations? Expert Rev Vaccines (2011) 0.92
Comparison of protective efficacy of subcutaneous versus intranasal immunization of mice with a Brucella melitensis lipopolysaccharide subunit vaccine. Infect Immun (2006) 0.91
Potential capsule switching from serogroup Y to B: The characterization of three such Neisseria meningitidis isolates causing invasive meningococcal disease in Canada. Can J Infect Dis Med Microbiol (2005) 0.90
An experimental outer membrane vesicle vaccine from N. meningitidis serogroup B strains that induces serum bactericidal activity to multiple serogroups. Vaccine (2011) 0.89
Protection of mice against brucellosis by intranasal immunization with Brucella melitensis lipopolysaccharide as a noncovalent complex with Neisseria meningitidis group B outer membrane protein. Infect Immun (2002) 0.88
A phase 1 study of a group B meningococcal native outer membrane vesicle vaccine made from a strain with deleted lpxL2 and synX and stable expression of opcA. Vaccine (2010) 0.87
Importance of antibodies to lipopolysaccharide in natural and vaccine-induced serum bactericidal activity against Neisseria meningitidis group B. Infect Immun (2011) 0.83
Molecular analysis of monoclonal antibodies to group variant capsular polysaccharide of Neisseria meningitidis: recurrent heavy chains and alternative light chain partners. Mol Immunol (2005) 0.81
Analysis of the bactericidal response to an experimental Neisseria meningitidis vesicle vaccine. Clin Vaccine Immunol (2012) 0.80
Phase I study of a Neisseria meningitidis liposomal vaccine containing purified outer membrane proteins and detoxified lipooligosaccharide. Vaccine (2011) 0.80
Plasma fibrinogen levels after vaccination with a native outer membrane vesicle vaccine for Neisseria meningitidis. Vaccine (2009) 0.75
Fulminant supraglottitis from Neisseria meningitidis. Emerg Infect Dis (2007) 0.75